Premium
Boosted protease inhibitors as a therapeutic option in the treatment of HIV‐infected children
Author(s) -
Ramos JT
Publication year - 2009
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2009.00728.x
Subject(s) - medicine , tolerability , human immunodeficiency virus (hiv) , antiretroviral therapy , intensive care medicine , drug , protease , protease inhibitor (pharmacology) , pharmacology , family medicine , viral load , adverse effect , biochemistry , chemistry , enzyme
Objective Paediatric HIV treatment must address various special considerations. Administration of pharmacokinetically enhanced protease inhibitors (PIs) can improve paediatric therapeutic outcomes. The objective of this study was to review the use of boosted PI regimens in children. Methods Systematic literature searches of published manuscripts and conference databases using generic drug names and specific keywords were performed to ensure thorough and balanced reporting of available data. Results Boosted PI regimens offer multiple options across a range of ages and are efficacious in naïve and experienced children; safety and tolerability are similar to those observed in adults. Novel boosted PI simplification approaches may foster adherence and diminish resistance. Conclusions Boosted PIs are key components of first‐ and second‐line treatments in children. Identifying factors associated with the response to highly active antiretroviral therapy in children may ultimately permit individualized therapies.